EPIRUS BIOPHARMACEUTICALS, INC.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "EPIRUS BIOPHARMACEUTICALS, INC."

Transcription

1 EPIRUS BIOPHARMACEUTICALS, INC. FORM 8-K (Current report filing) Filed 09/29/14 for the Period Ending 09/24/14 Address 699 BOYLSTON ST 8TH FLOOR BOSTON, MA Telephone (617) CIK Symbol EPRS SIC Code Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 Copyright 2016, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 24, 2014 EPIRUS BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Number) Identification No.) 699 Boylston Street Eighth Floor Boston, MA (Address of Principal Executive Offices) (Zip Code) Registrant s telephone number, including area code: (617) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))

3 Item 1.01 Entry into a Material Definitive Agreement. Livzon Collaboration Agreement On September 24, 2014, Epirus Switzerland GmbH ( Epirus ), a wholly-owned subsidiary of EPIRUS Biopharmaceuticals, Inc. (together with its subsidiaries, the Company ), entered into an Exclusive License and Collaboration Agreement (the Agreement ) with Livzon Mabpharm Inc. ( Livzon ) for the global development and commercialization of certain antibodies or related biological compounds, including the Company s BOW015, a biosimilar version of infliximab. Under the Agreement, Epirus and Livzon each granted the other party, in the other party s territory, exclusive, royalty-bearing licenses under certain patent rights and know-how to develop, manufacture and commercialize BOW015 and up to four additional compounds chosen by mutual agreement of the parties (collectively, the Collaboration Compounds ). Livzon s territory consists of China, Hong Kong, Macau and Taiwan (the Livzon Territory ), and the Company s territory consists of the rest of the world. The parties share pre-clinical development expenses for each Collaboration Compound based on certain factors specific to each compound. Each party bears the responsibility and expenses for clinical development and commercialization of each Collaboration Compound in its territory. Livzon will be the preferred supplier of each Collaboration Compound for pre-clinical, clinical, and commercialization purposes, subject to Livzon s satisfaction of certain performance criteria. In consideration for the license granted to Livzon to develop and commercialize BOW015, the Company is eligible to receive from Livzon a milestone payment of $2.5 million upon the achievement of a specified regulatory milestone in the Livzon Territory. The Company is also eligible to receive from Livzon tiered royalties based on a percentage of net sales of BOW015 products in the Livzon Territory ranging from the low- to high- single digits. Any future Collaboration Compounds have cross-milestone and royalty obligations in amounts to be mutually agreed upon at a later date. If not terminated earlier or extended by mutual agreement of the parties, the Agreement expires in its entirety twenty years from the effective date. Either party may terminate the agreement for any material breach by the other party that is not cured within a specified time period. Either party may also terminate the Agreement upon bankruptcy or insolvency of the other party or if the other party challenges any of the patents licensed to it under the Agreement. Amendment to Revenue and Negotiation Rights Agreement On September 24, 2014, the Company entered into an amendment (the Amendment ) to that certain Revenue and Negotiation Rights Agreement between the Company and Moksha8 Pharmaceuticals, Inc. ( Moksha8 ), dated as of December 31, 2010 (the Moksha8 Revenue Agreement ). Under the terms of the Moksha8 Revenue Agreement, the Company was required to pay to Moksha8 royalties based on nets sales of BOW015 by Epirus or its affiliates at a percentage in the very low double digits, and a portion of all licensing revenue received by Epirus from third parties to commercialize BOW015 at a percentage in the mid-teens, subject in each case to reduction in certain circumstances. The Moksha8 Revenue Agreement is further described in the Company s Quarterly Report on Form 10-Q for its quarter ended June 30, The Amendment amends the Moksha8 Revenue Agreement to terminate the Company s payment obligations with respect to products that are biosimilars to infliximab, which includes the Company s BOW015 product, in exchange for the Company s payment of $1.5 million in two installments. The foregoing description is a summary and is qualified in its entirety by reference to the full text of the Amendment, which is attached hereto as Exhibit 10.1 and incorporated herein by reference. 2

4 Item 7.01 Regulation FD. On September 25, 2014, the Company issued a press release announcing the execution of the Agreement. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 First Amendment to the Revenue and Negotiation Rights Agreement, dated as of September 24, 2014, by and between Epirus Switzerland GmbH and Moksha8 Pharmaceuticals, Inc Press release of EPIRUS Biopharmaceuticals, Inc. dated September 25,

5 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 29, EPIRUS BIOPHARMACEUTICALS, INC. By: /s/ Amit Munshi Name: Amit Munshi Title: President and Chief Executive Officer

6 EXHIBIT INDEX Exhibit Number Description 10.1 First Amendment to the Revenue and Negotiation Rights Agreement, dated as of September 24, 2014, by and between Epirus Switzerland GmbH and Moksha8 Pharmaceuticals, Inc Press release of EPIRUS Biopharmaceuticals, Inc. dated September 25,

7 By this private instrument, the Parties, FIRST AMENDMENT TO THE REVENUE AND NEGOTIATION RIGHTS AGREEMENT Exhibit 10.1 EXECUTION VERSION EPIRUS SWITZERLAND GMBH, a corporation organized under the laws of Switzerland, with registered office at General-Guisan-Strasse 6, 6303 Zug Switzerland (hereinafter referred to as EPIRUS ), and as a successor to FOURTEEN22, INC. ( FOURTEEN22 ), represented herein by its undersigned legal representative(s), and MOKSHA8 PHARMACEUTICALS, INC., a Delaware corporation with registered office at 1550 Liberty Ridge Drive, Suite 300, Wayne, PA (hereinafter referred to as MOKSHA8 ), represented herein by its undersigned legal representative(s), MOKSHA8 and EPIRUS referred to herein individually as a Party and collectively as the Parties, hereby amend the Revenue and Negotiation Rights Agreement entered into between the Parties on December 31, 2010 (the Agreement ; capitalized terms used herein without definition shall have the meanings given to them in the Agreement): THE PARTIES HEREIN AGREE to enter into this First Amendment to the Agreement, which shall be governed by the following provisions: 1. EPIRUS Buyout of World-wide Revenue Sharing Payments for the 015 Product. In exchange for the payments pursuant to Clause 2 below, the Parties agree that all payment obligations of EPIRUS under Article 2 of the Agreement in respect of the 015 Product shall be irrevocably extinguished and deemed paid in full, including amounts payable under (i) Section 2.1(c) of the Agreement in respect of any past or future Net Sales of the 015 Product by EPIRUS or its Affiliates, and (ii) Section 2.2(c) of the Agreement in respect of any past or future Licensing Revenue received by EPIRUS or its Affiliates for the 015 Product, in each case for all such amounts that would otherwise be payable under the Agreement in respect of any Net Sales and/or Licensing Revenue generated in the Territory for the 015 Product. 2. As full and valid consideration for the world-wide buyout of the 015 Product revenue sharing payments pursuant to Clause 1 above, EPIRUS shall pay to MOKSHA8 a total amount of 1.5 million US Dollars (USD 1,500,000.00) in two (2) installments: (a) Seven hundred and fifty thousand US Dollars (USD 750,000.00) within ten (10) days following the execution of this First Amendment; and (b) Seven hundred and fifty thousand US Dollars (USD 750,000.00) within ten (10) days following EPIRUS closing of its next Form S3 registered offering of common stock and, in any event, by no later than December 31, 2014.

8 3. The payments in Clause 2 shall be made by means of transfer to a bank account to be appointed by MOKSHA8 in writing. The evidence of the order of transfer to the MOKSHA8 bank account of the amount corresponded to the payments shall be considered receipt. For the avoidance of doubt, the Parties agree that (i) the payments in Clause 2 will be non-refundable, and (ii) pending the payment of the second installment amount under Clause 2(b) above, no revenue sharing payment in respect of the 015 Product shall be due or payable by EPIRUS under the Agreement, subject to its payment of such second installment amount as provided hereunder. 4. This Amendment shall be effective as of September 24, 2014 (the Amendment Effective Date ). 5. The Agreement, including all Exhibits thereto and this First Amendment constitute the entire agreement between the Parties in relation to the subject matter thereof and supersede all other prior and contemporaneous communications, negotiations, arrangements and agreements between the Parties, whether oral or in writing. Except for the provisions of the Agreement expressly amended by this Amendment, the remainder of the Agreement shall remain in full force and effect as provided therein. 6. This Amendment shall be deemed to have been drafted by both Parties, and ambiguities, if any, shall not be construed against either Party. 7. This First Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 8. The validity, performance, construction and effect of this Amendment shall be governed by the laws of the State of New York, without regard to any conflicts of laws principles. IN WITNESS WHEREOF, the Parties execute this First Amendment to the Agreement by each of their duly authorized representatives. [Signature page follows] 2

9 EPIRUS SWITZERLAND GMBH /s/ Amit Munshi Name: Amit Munshi Title: President & CEO MOKSHA8 PHARMACEUTICALS, INC. /s/ AG Howarth Name: AG Howarth Title: CFO 3

10 Exhibit 99.1 EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China Partners to develop, manufacture and commercialize up to five biosimilars, including EPIRUS BOW015, for Asian markets BOSTON, September 25, EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc. (Livzon), a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs. Livzon was also a principal investor in the $36 million private financing round EPIRUS closed in April 2014, prior to becoming a public company. Under the terms of the agreement, EPIRUS and Livzon will work together to develop, manufacture, and commercialize up to five biosimilar products. The first collaboration product is EPIRUS Remicade biosimilar BOW015 (infliximab), which was recently approved in India. Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan. Livzon will also serve as the preferred supplier of BOW015 in these territories, following a transfer of EPIRUS SCALE manufacturing platform. Livzon will be responsible for all commercialization activities in its territories. We have established a significant collaboration with a strong partner in a compelling market, said Amit Munshi, president and CEO of EPIRUS. This agreement also reinforces the importance of our SCALE manufacturing platform for in market production globally. Daotian Fu, Ph.D., CEO of Livzon Mabpharm, Inc., said, EPIRUS robust pipeline, business strategy and experienced management coupled with the market potential of biosimilars, made this an exciting collaboration for Livzon. We look forward to building a substantial biosimilars business for the China market. Dr. Fu is also a member of the EPIRUS board of directors. About EPIRUS EPIRUS is building a global biosimilar enterprise to improve patient access to important medicines. EPIRUS pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab), and BOW030 (bevacizumab). The reference products for these product candidates Remicade, Humira, and Avastin, respectively together generated $26.2 billion in global sales in

11 EPIRUS strategy for commercial success relies on targeted approaches for diverse global markets. For emerging markets with accessible regulatory frameworks for biosimilars, EPIRUS develops partnerships with local companies to accelerate regulatory approval and commercialize its products. For high-growth global markets where local manufacturing confers strategic and operational advantages, EPIRUS intends to use its SCALE platform to deliver an In Market, For Market manufacturing solution with local partners. For large markets with an established biosimilar regulatory framework, such as Europe, EPIRUS plans to commercialize its products using a combination of direct sales and local distributors. More information about EPIRUS can be found at About BOW015 BOW015 is a biosimilar version of infliximab, a biologic therapy marketed under the name Remicade. EPIRUS has previously reported positive Phase 1 and Phase 3 clinical data for BOW015. The Phase 3 trial previously met its predefined endpoint and demonstrated the comparability of BOW015 to Remicade, as measured by ACR20 response in severe rheumatoid arthritis (RA) patients. The study also showed no meaningful differences between BOW015 and Remicade with regard to safety or immunogenicity. Recently, Epirus announced 58 week data for its Phase 3 trial, which demonstrated therapeutic equivalence to Remicade and confirmed the safety of switching from Remicade to BOW015. More data on the Phase 3 study is available at EPIRUS is actively progressing applications for marketing approval for BOW015 in targeted global markets. EPIRUS also plans to initiate an additional Phase 3 trial in Europe in early About Livzon Mabpharm, Inc. Founded in 2010, Livzon Mabpharm, Inc. is one of the major biotechnology companies to enter biologics research and development in China. It is mainly focused on development, manufacturing and sale of antibody-based drugs. It is equipped with a world-class technical and scientific research team, core technology platforms, and advanced R&D facilities. The company s controlling shareholder is Livzon Pharmaceutical Group, Inc. ( Livzon, a pharmaceutical 2

12 listed company in Mainland China and in Hong Kong (Stock code: sz, HK)), which holds 51% shares of Livzon Mabpharm, Inc. Livzon is a diversified pharmaceutical enterprise integrating development & research, production and sales of pharmaceutical products, operating to manufacture drug products, bulk medicines and intermediates, as well as diagnostic reagents and equipment. Livzon Mabpharm, Inc. was founded as the strategic R&D transformation of Livzon Pharmaceutical Group. Inc., focusing on development of antibody based drugs and vaccines. More information about Livzon can be found at Forward Looking Statements Any statements made herein relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including the development and prospects of BOW015 and EPIRUS collaboration with Livzon, are forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of In addition, when or if used in this document, the words may, could, should, anticipate, believe, estimate, expect, intend, plan, predict and similar expressions and their variants, as they relate to EPIRUS or its management, before or after the recent Zalicus merger, may identify forward-looking statements. EPIRUS cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by EPIRUS to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of EPIRUS proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that EPIRUS may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect EPIRUS business, financial conditions and results of operations are contained in EPIRUS filings with the U.S. Securities and Exchange Commission, which are available at Other risks and uncertainties are more fully described in EPIRUS filings with the U.S. Securities and Exchange Commission, which are available at Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made herein speak only as of the date stated herein, and subsequent events and developments may cause EPIRUS expectations and beliefs to change. 3

13 While EPIRUS may elect to update these forward-looking statements publicly at some point in the future, EPIRUS specifically disclaims any duty or obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forwardlooking statements should not be relied upon as representing EPIRUS views as of any date after the date stated herein. ### 4

14 For Inquiries: Russo Partners LLC Tony Russo, or Andrea Flynn, Remicade is a registered trademark of Johnson and Johnson (www.jnj.com) Humira is a registered trademark of AbbVie (www.abbvie.com) Avastin is a registered trademark of Genentech (www.gene.com) 5

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code

More information

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 HORIZON PHARMA PLC FORM 8-K (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 Telephone 011-353-1-772-2100 CIK 0001492426 Symbol HZNP SIC Code 2834 - Pharmaceutical Preparations Industry

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

IMPERIAL HOLDINGS, INC.

IMPERIAL HOLDINGS, INC. IMPERIAL HOLDINGS, INC. FORM 8-K (Current report filing) Filed 01/03/12 for the Period Ending 12/30/11 Address 701 PARK OF COMMERCE BOULEVARD SUITE 301 BOCA RATON, FL 33487 Telephone 561-995-4200 CIK 0001494448

More information

IMS HEALTH HOLDINGS, INC.

IMS HEALTH HOLDINGS, INC. IMS HEALTH HOLDINGS, INC. FORM 8-K (Current report filing) Filed 06/30/14 for the Period Ending 06/30/14 Address 83 WOOSTER HEIGHTS ROAD DANBURY, CT 06810 Telephone 203-448-4600 CIK 0001595262 Symbol IMS

More information

SORRENTO THERAPEUTICS, INC.

SORRENTO THERAPEUTICS, INC. ˆ200F@WVSVmdG1Yng+Š 200F@WVSVmdG1Yng+ AZ0151AC599817 11.3.10 SWRvelaj0nb 31-Jul-2013 16:51 EST 577580 TX 1 3* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant

More information

Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cellular Biomedicine Group, Inc. Form: 8-K Date Filed: 2014-07-31 Corporate Issuer CIK: 1378624 Symbol: CBMG SIC Code: 2836 Copyright 2014, Issuer Direct Corporation.

More information

HOME LOAN SERVICING SOLUTIONS, LTD.

HOME LOAN SERVICING SOLUTIONS, LTD. HOME LOAN SERVICING SOLUTIONS, LTD. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 04/24/15 Telephone (345) 945-3727 CIK 0001513161 Symbol HLSS SIC Code 6162 - Mortgage Bankers

More information

JACOBS ENGINEERING GROUP INC /DE/

JACOBS ENGINEERING GROUP INC /DE/ JACOBS ENGINEERING GROUP INC /DE/ FORM 8-K (Current report filing) Filed 04/29/14 for the Period Ending 04/28/14 Address 155 NORTH LAKE AVENUE PASADENA, CA 91101 Telephone 6265783500 CIK 0000052988 Symbol

More information

VISA INC. FORM 8-K. (Current report filing) Filed 02/27/15 for the Period Ending 02/27/15

VISA INC. FORM 8-K. (Current report filing) Filed 02/27/15 for the Period Ending 02/27/15 FORM 8-K (Current report filing) Filed 02/27/15 for the Period Ending 02/27/15 Address P.O. BOX 8999 SAN FRANCISCO, CA 94128-8999 Telephone (415) 932-2100 CIK 0001403161 Symbol V SIC Code 7389 - Business

More information

Delaware 000-50703 14-1839426 (State or other jurisdiction of incorporation)

Delaware 000-50703 14-1839426 (State or other jurisdiction of incorporation) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 7, 2014 (Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

GLADSTONE CAPITAL CORP

GLADSTONE CAPITAL CORP GLADSTONE CAPITAL CORP FORM 8-K (Current report filing) Filed 06/23/15 for the Period Ending 06/19/15 Address 1521 WESTBRANCH DRIVE SUITE 100 MCLEAN, VA 22102 Telephone 703-287-5800 CIK 0001143513 Symbol

More information

QUALCOMM INC/DE FORM 8-K. (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15

QUALCOMM INC/DE FORM 8-K. (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15 QUALCOMM INC/DE FORM 8-K (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15 Address 5775 MOREHOUSE DR SAN DIEGO, CA 92121 Telephone 8585871121 CIK 0000804328 Symbol QCOM SIC Code 3663

More information

APPLE INC FORM 8-K. (Current report filing) Filed 06/06/14 for the Period Ending 06/06/14

APPLE INC FORM 8-K. (Current report filing) Filed 06/06/14 for the Period Ending 06/06/14 APPLE INC FORM 8-K (Current report filing) Filed 06/06/14 for the Period Ending 06/06/14 Address ONE INFINITE LOOP CUPERTINO, CA 95014 Telephone (408) 996-1010 CIK 0000320193 Symbol AAPL SIC Code 3571

More information

ABM INDUSTRIES INC /DE/

ABM INDUSTRIES INC /DE/ ABM INDUSTRIES INC /DE/ FORM 8-K (Current report filing) Filed 10/14/11 for the Period Ending 10/11/11 Address 551 FIFTH AVENUE SUITE 300 NEW YORK, NY 10176 Telephone 212 297-0200 CIK 0000771497 Symbol

More information

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter)

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

EXPEDIA, INC. FORM 8-K. (Current report filing) Filed 11/14/14 for the Period Ending 11/13/14

EXPEDIA, INC. FORM 8-K. (Current report filing) Filed 11/14/14 for the Period Ending 11/13/14 EXPEDIA, INC. FORM 8-K (Current report filing) Filed 11/14/14 for the Period Ending 11/13/14 Address 333 108TH AVENUE NE BELLEVUE, WA 98004 Telephone (425) 679-7200 CIK 0001324424 Symbol EXPE SIC Code

More information

IDEXX LABORATORIES, INC.

IDEXX LABORATORIES, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

SPHERIX INCORPORATED (Exact Name of Registrant as Specified in Charter)

SPHERIX INCORPORATED (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FORM 8-K. CREATIVE REALITIES, INC. (Exact name of registrant as specified in its charter)

FORM 8-K. CREATIVE REALITIES, INC. (Exact name of registrant as specified in its charter) 8-K 1 f8k091514_creativerealities.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE

More information

GARDNER DENVER INC FORM 8-K. (Current report filing) Filed 11/19/12 for the Period Ending 11/12/12

GARDNER DENVER INC FORM 8-K. (Current report filing) Filed 11/19/12 for the Period Ending 11/12/12 GARDNER DENVER INC FORM 8-K (Current report filing) Filed 11/19/12 for the Period Ending 11/12/12 Address 1500 LIBERTY RIDGE DRIVE, SUITE 3000 WAYNE, PA 19087 Telephone 6102492000 CIK 0000916459 SIC Code

More information

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 01/29/2009 Filed Period 01/28/2009

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 01/29/2009 Filed Period 01/28/2009 JER INVESTORS TRUST INC (JERT) 8-K Current report filing Filed on 01/29/2009 Filed Period 01/28/2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant

More information

UNITED THERAPEUTICS CORP

UNITED THERAPEUTICS CORP UNITED THERAPEUTICS CORP FORM 8-K (Current report filing) Filed 11/13/14 for the Period Ending 11/11/14 Address 1040 SPRING ST SILVER SPRING, MD 20910 Telephone 3016089292 CIK 0001082554 Symbol UTHR SIC

More information

GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC.

GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC. GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 07/14/15 Address 11921 FREEDOM DRIVE, SUITE 550 TWO FOUNTAIN SQUARE RESTON, VA 20190

More information

SPHERIX INC FORM 8-K. (Current report filing) Filed 05/24/16 for the Period Ending 05/23/16

SPHERIX INC FORM 8-K. (Current report filing) Filed 05/24/16 for the Period Ending 05/23/16 SPHERIX INC FORM 8-K (Current report filing) Filed 05/24/16 for the Period Ending 05/23/16 Address 1350 AVENUE OF THE AMERICAS FL 2 NEW YORK, NY 10019 Telephone 347-321-7646 CIK 0000012239 Symbol SPEX

More information

INTERNAP CORP FORM 8-K. (Current report filing) Filed 10/02/14 for the Period Ending 10/02/14

INTERNAP CORP FORM 8-K. (Current report filing) Filed 10/02/14 for the Period Ending 10/02/14 INTERNAP CORP FORM 8-K (Current report filing) Filed 10/02/14 for the Period Ending 10/02/14 Address ONE RAVINIA DRIVE SUITE 1300 ATLANTA, GA 30346 Telephone 404-302-9700 CIK 0001056386 Symbol INAP SIC

More information

ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)

ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

CERIDIAN CORPORATION

CERIDIAN CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter)

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

U S PHYSICAL THERAPY INC /NV

U S PHYSICAL THERAPY INC /NV U S PHYSICAL THERAPY INC /NV FORM 8-K (Current report filing) Filed 08/04/14 for the Period Ending 08/04/14 Address 1300 WEST SAM HOUSTON PARKWAY SUITE 300 HOUSTON, TX 77043 Telephone 7132977000 CIK 0000885978

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

P. H. Glatfelter Company (Exact name of registrant as specified in its charter)

P. H. Glatfelter Company (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

National American University Holdings, Inc.

National American University Holdings, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING National American University Holdings, Inc. Form: 8-K Date Filed: 2015-08-13 Corporate Issuer CIK: 1399855 Copyright 2015, Issuer Direct Corporation. All Right

More information

RICH PHARMACEUTICALS, INC.

RICH PHARMACEUTICALS, INC. RICH PHARMACEUTICALS, INC. FORM 8-K (Current report filing) Filed 10/08/14 for the Period Ending 10/06/14 Address 9595 WILSHIRE BLVD., SUITE 900 BEVERLY HILLS, CA 90212 Telephone (424) 230-7001 CIK 0001504389

More information

FXCM INC. FORM 8-K. (Current report filing) Filed 09/09/15 for the Period Ending 09/03/15

FXCM INC. FORM 8-K. (Current report filing) Filed 09/09/15 for the Period Ending 09/03/15 FXCM INC. FORM 8-K (Current report filing) Filed 09/09/15 for the Period Ending 09/03/15 Address 55 WATER ST. FL 50 NEW YORK, NY 10041 Telephone 6464322241 CIK 0001499912 Symbol FXCM SIC Code 6200 - Security

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) the Securities Exchange Act 1934 Date Report (Date Earliest Event Reported):

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

BIOLIFE SOLUTIONS INC

BIOLIFE SOLUTIONS INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING BIOLIFE SOLUTIONS INC Form: 8-K Date Filed: 2016-01-07 Corporate Issuer CIK: 834365 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

FORM 8-K SPDR GOLD TRUST SPONSORED BY WORLD GOLD TRUST SERVICES, LLC

FORM 8-K SPDR GOLD TRUST SPONSORED BY WORLD GOLD TRUST SERVICES, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

DELTA TUCKER HOLDINGS, INC.

DELTA TUCKER HOLDINGS, INC. DELTA TUCKER HOLDINGS, INC. FORM 8-K (Current report filing) Filed 10/30/14 for the Period Ending 10/30/14 Address 13601 NORTH FREEWAY, SUITE 200 FORT WORTH, TX 76177 Telephone 571-722-0210 CIK 0001514226

More information

STEINWAY MUSICAL INSTRUMENTS INC

STEINWAY MUSICAL INSTRUMENTS INC STEINWAY MUSICAL INSTRUMENTS INC FORM 8-K (Current report filing) Filed 12/26/12 for the Period Ending 12/20/12 Address 800 SOUTH STREET SUITE 305 WALTHAM, MA 02453-1472 Telephone 7818949770 CIK 0000911583

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UBIQUITY, INC. FORM 8-K. (Current report filing) Filed 08/12/14 for the Period Ending 07/18/14

UBIQUITY, INC. FORM 8-K. (Current report filing) Filed 08/12/14 for the Period Ending 07/18/14 UBIQUITY, INC. FORM 8-K (Current report filing) Filed 08/12/14 for the Period Ending 07/18/14 Address 9801 RESEARCH DRIVE IRVINE,, CA 92618 Telephone 7029970504 CIK 0001538329 Symbol UBIQ SIC Code 7374

More information

BRIDGEPOINT EDUCATION INC

BRIDGEPOINT EDUCATION INC BRIDGEPOINT EDUCATION INC FORM 8-K (Current report filing) Filed 11/12/13 for the Period Ending 11/08/13 Address 13500 EVENING CREEK DR. #600 SAN DIEGO, CA 92128 Telephone 858-668-2586 CIK 0001305323 Symbol

More information

Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ABBVIE INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ABBVIE INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

GSV CAPITAL CORP. FORM 8-K. (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15

GSV CAPITAL CORP. FORM 8-K. (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15 GSV CAPITAL CORP. FORM 8-K (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15 Address 2925 WOODSIDE ROAD WOODSIDE, CA 94062 Telephone (650) 235-4777 CIK 0001509470 Symbol GSVC Industry

More information

HUDSON CITY BANCORP INC Filed by M&T BANK CORP

HUDSON CITY BANCORP INC Filed by M&T BANK CORP HUDSON CITY BANCORP INC Filed by M&T BANK CORP FORM 425 (Filing of certain prospectuses and communications in connection with business combination transactions) Filed 04/15/13 Address WEST 80 CENTURY RD

More information

Victory Energy Corporation (Exact name of registrant as specified in its charter)

Victory Energy Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

NEVRO CORP FORM 8-K. (Current report filing) Filed 04/09/15 for the Period Ending 04/09/15

NEVRO CORP FORM 8-K. (Current report filing) Filed 04/09/15 for the Period Ending 04/09/15 NEVRO CORP FORM 8-K (Current report filing) Filed 04/09/15 for the Period Ending 04/09/15 Address 4040 CAMPBELL AVENUE SUITE 210 MENLO PARK, CA 94025 Telephone 650-251-0005 CIK 0001444380 Symbol NVRO SIC

More information

Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

EVERYDAY HEALTH, INC.

EVERYDAY HEALTH, INC. EVERYDAY HEALTH, INC. FORM 8-K (Current report filing) Filed 05/11/15 for the Period Ending 05/11/15 Address 345 HUDSON STREET 16TH FLOOR NEW YORK, NY 10014 Telephone 718-797-0722 CIK 0001358483 Symbol

More information

SECURITIES AND EXCHANGE COMMISSION FORM 8-K GENSPERA, INC.

SECURITIES AND EXCHANGE COMMISSION FORM 8-K GENSPERA, INC. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

More information

ONCOTHYREON INC. FORM 424B3. (Prospectus filed pursuant to Rule 424(b)(3)) Filed 12/22/10

ONCOTHYREON INC. FORM 424B3. (Prospectus filed pursuant to Rule 424(b)(3)) Filed 12/22/10 ONCOTHYREON INC. FORM 424B3 (Prospectus filed pursuant to Rule 424(b)(3)) Filed 12/22/10 Address 2601 FOURTH AVENUE SUITE 500 SEATTLE, WA 98121 Telephone (206) 801-2100 CIK 0001412067 Symbol ONTY SIC Code

More information

DIFFUSION PHARMACEUTICALS INC.

DIFFUSION PHARMACEUTICALS INC. DIFFUSION PHARMACEUTICALS INC. FORM 8-K (Current report filing) Filed 03/07/14 for the Period Ending 03/07/14 Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE, VA 22902 Telephone (434) 220-0718 CIK 0001053691

More information

INFOSPACE INC FORM 8-K. (Current report filing) Filed 12/21/06 for the Period Ending 12/21/06

INFOSPACE INC FORM 8-K. (Current report filing) Filed 12/21/06 for the Period Ending 12/21/06 INFOSPACE INC FORM 8-K (Current report filing) Filed 12/21/06 for the Period Ending 12/21/06 Address 601 108TH AVE NE SUITE 1200 BELLEVUE, WA 98004 Telephone 4258821602 CIK 0001068875 Symbol INSP SIC Code

More information

GRUBB & ELLIS HEALTHCARE REIT, INC.

GRUBB & ELLIS HEALTHCARE REIT, INC. GRUBB & ELLIS HEALTHCARE REIT, INC. FORM 8-K (Current report filing) Filed 04/21/09 for the Period Ending 04/21/09 Address 1551 N. TUSTIN AVENUE SUITE 300 SANTA ANA, CA 92705 Telephone 714-667-8252 CIK

More information

DONALDSON CO INC FORM 8-K. (Current report filing) Filed 03/12/15 for the Period Ending 03/09/15

DONALDSON CO INC FORM 8-K. (Current report filing) Filed 03/12/15 for the Period Ending 03/09/15 DONALDSON CO INC FORM 8-K (Current report filing) Filed 03/12/15 for the Period Ending 03/09/15 Address 1400 W. 94TH ST. MINNEAPOLIS, MN 55431 Telephone 6128873131 CIK 0000029644 Symbol DCI SIC Code 3564

More information

PACIFIC ETHANOL, INC. (Exact name of registrant as specified in its charter)

PACIFIC ETHANOL, INC. (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported)

More information

MOOG INC. (Exact name of registrant as specified in its charter)

MOOG INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Form 8-K. Shepherd s Finance, LLC (Exact name of registrant as specified in its charter)

Form 8-K. Shepherd s Finance, LLC (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

INCONTACT, INC. FORM 8-K. (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15

INCONTACT, INC. FORM 8-K. (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15 INCONTACT, INC. FORM 8-K (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15 Address 7730 S. UNION PARK AVE., SUITE 500 NONE MIDVALE, UT 84047 Telephone (801) 320-3300 CIK 0001087934

More information

AMERISAFE INC FORM 8-K. (Current report filing) Filed 04/29/15 for the Period Ending 04/29/15

AMERISAFE INC FORM 8-K. (Current report filing) Filed 04/29/15 for the Period Ending 04/29/15 AMERISAFE INC FORM 8-K (Current report filing) Filed 04/29/15 for the Period Ending 04/29/15 Address 2301 HIGHWAY 190 WEST DERIDDER, LA 70634 Telephone 337-463-9052 CIK 0001018979 Symbol AMSF SIC Code

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 13, 2012 Date

More information

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 04/11/2007 Filed Period 04/11/2007

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 04/11/2007 Filed Period 04/11/2007 JER INVESTORS TRUST INC (JERT) 8-K Current report filing Filed on 04/11/2007 Filed Period 04/11/2007 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

UBIQUITY, INC. FORM 8-K. (Current report filing) Filed 03/20/15 for the Period Ending 03/19/15

UBIQUITY, INC. FORM 8-K. (Current report filing) Filed 03/20/15 for the Period Ending 03/19/15 UBIQUITY, INC. FORM 8-K (Current report filing) Filed 03/20/15 for the Period Ending 03/19/15 Address 9801 RESEARCH DRIVE IRVINE,, CA 92618 Telephone 7029970504 CIK 0001538329 Symbol UBIQ SIC Code 7374

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 8, 2014 Date of Report (Date of

More information

Moody National REIT II, Inc.

Moody National REIT II, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

INTERNATIONAL BANCSHARES CORPORATION (Exact Name of registrant as specified in its charter)

INTERNATIONAL BANCSHARES CORPORATION (Exact Name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest

More information

FORM 8-K. New Energy Technologies, Inc. (Exact name of registrant as specified in its charter)

FORM 8-K. New Energy Technologies, Inc. (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 16, 2013 Date of Report (Date of earliest

More information

NBCUNIVERSAL MEDIA, LLC

NBCUNIVERSAL MEDIA, LLC NBCUNIVERSAL MEDIA, LLC FORM 8-K (Current report filing) Filed 12/19/13 for the Period Ending 12/18/13 Address 30 ROCKEFELLER PLAZA NEW YORK, NY 10112 Telephone 2126644444 CIK 0000902739 SIC Code 4841

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Form 8-K. Shepherd s Finance, LLC (Exact name of registrant as specified in its charter)

Form 8-K. Shepherd s Finance, LLC (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

NEVADA GOLD & CASINOS INC

NEVADA GOLD & CASINOS INC NEVADA GOLD & CASINOS INC FORM 8-K (Current report filing) Filed 08/30/05 for the Period Ending 08/24/05 Address 50 BRIAR HOLLOW LANE, SUITE 500W HOUSTON, TX 77027 Telephone (713) 621-2245 CIK 0000277058

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest

More information

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter)

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 15, 2015 (Date

More information

eon Communications Corporation

eon Communications Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

ANALOG DEVICES INC FORM 8-K. (Current report filing) Filed 06/18/15 for the Period Ending 06/17/15

ANALOG DEVICES INC FORM 8-K. (Current report filing) Filed 06/18/15 for the Period Ending 06/17/15 ANALOG DEVICES INC FORM 8-K (Current report filing) Filed 06/18/15 for the Period Ending 06/17/15 Address ONE TECHNOLOGY WAY NORWOOD, MA 02062 Telephone 7813294700 CIK 0000006281 Symbol ADI SIC Code 3674

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported):

More information

SYNACOR, INC. FORM 8-K. (Current report filing) Filed 08/18/15 for the Period Ending 08/18/15

SYNACOR, INC. FORM 8-K. (Current report filing) Filed 08/18/15 for the Period Ending 08/18/15 SYNACOR, INC. FORM 8-K (Current report filing) Filed 08/18/15 for the Period Ending 08/18/15 Address 40 LARIVIERE DRIVE SUITE 300 BUFFALO, NY 14202 Telephone 716-853-1362 CIK 0001408278 Symbol SYNC SIC

More information

SEQUENTIAL BRANDS GROUP, INC.

SEQUENTIAL BRANDS GROUP, INC. SEQUENTIAL BRANDS GROUP, INC. FORM 8-K (Current report filing) Filed 08/03/10 for the Period Ending 07/28/10 Address 1065 AVENUE OF AMERICAS SUITE 1705 NEW YORK, NY 10018 Telephone 213-745-2123 CIK 0000791770

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event

More information

United States Securities and Exchange Commission Washington, DC Form 8-K CURRENT REPORT

United States Securities and Exchange Commission Washington, DC Form 8-K CURRENT REPORT United States Securities and Exchange Commission Washington, DC 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

NAKED BRAND GROUP INC. (Exact name of registrant as specified in its charter)

NAKED BRAND GROUP INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

SANTANDER DRIVE AUTO RECEIVABLES LLC

SANTANDER DRIVE AUTO RECEIVABLES LLC SANTANDER DRIVE AUTO RECEIVABLES LLC FORM 8-K (Current report filing) Filed 03/12/13 for the Period Ending 03/06/13 Address 8585 NORTH STEMMONS FREEWAY SUITE 1100-N DALLAS, TX 75247 Telephone 214-237-3530

More information

NORDSON CORP FORM 8-K. (Current report filing) Filed 05/21/12 for the Period Ending 05/18/12

NORDSON CORP FORM 8-K. (Current report filing) Filed 05/21/12 for the Period Ending 05/18/12 NORDSON CORP FORM 8-K (Current report filing) Filed 05/21/12 for the Period Ending 05/18/12 Address 28601 CLEMENS RD WESTLAKE, OH 44145 Telephone 4408921580 CIK 0000072331 Symbol NDSN SIC Code 3569 - General

More information

VECTOR GROUP LTD FORM 8-K. (Current report filing) Filed 07/30/14 for the Period Ending 07/30/14

VECTOR GROUP LTD FORM 8-K. (Current report filing) Filed 07/30/14 for the Period Ending 07/30/14 VECTOR GROUP LTD FORM 8-K (Current report filing) Filed 07/30/14 for the Period Ending 07/30/14 Address 4400 BISCAYNE BOULEVARD 10TH FLOOR MIAMI, FL 33137 Telephone 3055798000 CIK 0000059440 Symbol VGR

More information

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter)

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 9, 2014 (Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

BIO KEY INTERNATIONAL INC

BIO KEY INTERNATIONAL INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING BIO KEY INTERNATIONAL INC Form: 8-K Date Filed: 2011-03-16 Corporate Issuer CIK: 1019034 Symbol: BKYI Copyright 2014, Issuer Direct Corporation. All Right

More information

GULFPORT ENERGY CORPORATION

GULFPORT ENERGY CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities exchange act of 1934 Date of report (Date of earliest event

More information

OVERSTOCK.COM, INC FORM 8-K. (Current report filing) Filed 03/11/14 for the Period Ending 03/06/14

OVERSTOCK.COM, INC FORM 8-K. (Current report filing) Filed 03/11/14 for the Period Ending 03/06/14 OVERSTOCK.COM, INC FORM 8-K (Current report filing) Filed 03/11/14 for the Period Ending 03/06/14 Address 6350 SOUTH 3000 EAST SALT LAKE CITY, UT 84121 Telephone 8019473100 CIK 0001130713 Symbol OSTK SIC

More information